PharmiWeb

Kelonia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KLN-1010, an in vivo BCMA CAR-T Therapy for Relapsed and Refract…

U.S. IND represents the second regulatory clearance for KLN-1010 and enables the first multi-center clinical trial in the U.S ...
Santé log

Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that patient dosing is now ...
Computer Weekly

CCRC says multiple Post Office software systems potentially implicated in miscarriages of justice

Statutory body said its work has widened to multiple IT systems, and could even look at potential Post Office miscarriages of ...
Neurology Advisor

Alixorexton Designated Breakthrough Therapy for Narcolepsy Type 1

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).
Le Lézard

Acertis Pharmaceuticals Licenses U.S. Commercial Rights to Licart® from IBSA

Acertis Pharmaceuticals, a specialty pharmaceutical company focused on delivering differentiated therapies to patients, today announced that it has entered into an exclusive agreement with Swiss ...